S. 3466: Accelerating New Pharmaceutical Competition Act

A bill to allow sponsors of certain new drug applications to rely upon investigations conducted in certain foreign countries, and for other purposes.

The bill’s titles are written by its sponsor.

What you can do



Sep 29, 2016


Referred to Committee on Sep 29, 2016

This bill was assigned to a congressional committee on September 29, 2016, which will consider it before possibly sending it on to the House or Senate as a whole.


Rand Paul

Junior Senator from Kentucky



Not available yet.


1% chance of being enacted according to PredictGov (details)


Sep 29, 2016

This is the first step in the legislative process.

Reported by Committee

Passed Senate

Passed House

Signed by the President

S. 3466 is a bill in the United States Congress.

A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

How to cite this information.

We recommend the following MLA-formatted citation when using the information you see here in academic work:

“S. 3466 — 114th Congress: Accelerating New Pharmaceutical Competition Act.” www.GovTrack.us. 2016. October 23, 2016 <https://www.govtrack.us/congress/bills/114/s3466>

Where is this information from?

GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.